EHL BIO Cell Technology Patents: Setting New Standards in Regenerative Medicine

Quick answer

EHL BIO holds multiple advanced cell technology patents, including 15-PGDH Inhibitor technology, SVF isolation kits from fat, and high-purity urine-derived stem cell cultivation. These technologies are certified by Korean government agencies and have consistently received prestigious industrial innovation awards.

Key takeaways

Patented SVF cell isolation kits for maximum precision and promoting safety in cell preparation.
15-PGDH Inhibitor technology focused on vascular maintenance and hair growth stimulation.
Expertise in culturing adipose and urine-derived stem cells for targeted body restoration.
Recipient of the IR52 Jang Young-shil Award 2025 for KDSTEM® cell therapy production innovation.

Advancements in Patents and Intellectual Property

EHL BIO operates as a leader in regenerative medicine R&D, with patents covering key technological areas central to modern maintenance. A standout innovation is the 15-PGDH Inhibitor technology, which involves inhibitory substances beneficial for preventing and supporting the care of cardiovascular, digestive, and renal conditions. This also includes specialized formulations to promote hair growth.

The company has also secured patents for Stromal Vascular Fraction (SVF) isolation kits from adipose tissue, enhancing efficiency and precision in stem cell collection. These processes are designed to promote safety in cell therapy preparation, ensuring that the cells used are of high quality and ready for further cultivation in EHL BIO's advanced laboratory facilities.

Urine-Derived Cell Innovation and Quality Recognition

EHL BIO's technological distinction extends to the development of patented technology for isolating and culturing high-purity urine-derived stem cells (UDSCs). This non-invasive innovation allows for sample collection via urine. The technology features the expression of Klotho protein, known for antioxidant properties and supporting the reduction of renal fibrosis, currently undergoing safety evaluation according to EHL team assessments.

Such advancements led EHL BIO to receive the prestigious 'IR52 Jang Young-shil Award' in 2025 for technological innovation, an award recognizing industrial success in Korea. The committee evaluated the high-purity cell isolation and culture systems, along with the quality management of the KDSTEM® product. This represents a significant milestone for the company in setting new standards for the biotechnology market.

We focus on developing next-generation biologics and patented innovations so that advanced regenerative medicine provides maximum benefit towards physical restoration goals.

GMP Standards and Quality Control

All EHL BIO patented technologies are driven within GMP-certified manufacturing centers approved by the Korean MFDS. We possess Class 100 facilities and an integrated cell storage system capable of supporting 6,000 lots per year.

The research and production center is equipped with high-standard devices such as Biological Safety Cabinets (BSC), AHU air management with HEPA filters, and liquid nitrogen tanks for cryopreservation at -196°C to ensure optimal cell viability. EHL BIO's specialized cultivation technology produces cell yields up to 1,000 times higher than average, making cell therapy restoration feasible and practically accessible.

Technological Applications in Regenerative and Aesthetic Medicine

Restoration goals and quality of life are EHL BIO's priorities. Our patented technologies are applied in anti-aging and aesthetics, such as developing stem cell-derived Exosomes—nano-sized vesicles that facilitate cell communication and tissue regeneration. Premium skin booster products like 'klosome' and 'Cellon Skin' are the results of combining anti-aging proteins with Conditioned Media rich in growth factors and collagen.

These innovations have been evaluated for efficacy in wrinkle care, promoting elasticity, and brightening the skin, having undergone rigorous safety testing per Korean MFDS standards. Integrating medical and pharmaceutical technologies is the ultimate goal of MD Hong-gi Lee, CEO of EHL BIO, to enhance quality of life through partnership networks in Korea and Thailand.

Frequently asked questions

What makes EHL BIO's patented technology unique?

It stands out with cell isolation and culture technology that produces yields 1,000 times higher than standard methods, alongside high purity standards and recognized quality management.

What does EHL BIO's GMP standard cover?

It covers Class 100 facilities, HEPA air filtration, Biological Safety Cabinets, and a cryopreservation storage system that maintains cell quality at a high level.

What are the restoration goals using EHL BIO's patented technology?

It focuses on body restoration through therapeutic cell products (such as ADSTEM, KDSTEM) and premium skin care products like klosome and Cellon Skin that focus on cellular-level care for improved quality of life according to EHL team assessments.